Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer

BackgroundViscum album (VA) preparations have been used as a complimentary therapy in cancer. In addition to their cytotoxic properties, they have also been shown to have immunostimulatory properties. In the present study, we examine the hypothesis that the VA preparations induce activation of human DC that facilitates effective tumor regression.MethodsFour day old monocyte-derived immature DCs were treated with VA Qu Spez at 5, 10 and 15 μg/ml for 48 hrs. The expression of surface molecules was analyzed by flow cytometry. The ability of Qu Spez-educated DC to stimulate T cells was analyzed by allogeneic mixed lymphocyte reaction and activation of Melan-A/MART-1-specific M77-80 CD8+T cells. Cytokines in cell free culture supernatant was analyzed by cytokine bead array assay.ResultsVA Qu Spez stimulated DCs presented with increased expression of antigen presenting molecule HLA-DR and of co-stimulatory molecules CD40, CD80 and CD86. The VA Qu Spez also induced the secretion of inflammatory cytokines IL-6 and IL-8. Further, Qu Spez-educated DC stimulated CD4+T cells in a allogeneic mixed lymphocyte reaction and activated melanoma antigen Melan-A/MART-1-specific M77-80 CD8+T cells as evidenced by increased secretion of TNF-α and IFNγ.ConclusionThe VA preparations stimulate the maturation and activation of human DCs, which may facilitate anti-tumoral immune responses. These results should assist in understanding the immunostimulatory properties of VA preparations and improving the therapeutic strategies.

[1]  A. Büssing,et al.  Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. , 1999, Anticancer research.

[2]  R. Steinman,et al.  Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells , 1998, The Journal of experimental medicine.

[3]  A. Büssing,et al.  Intracellular expression of IL-4 and inhibition of IFN-gamma by extracts from European mistletoe is related to induction of apoptosis. , 2000, Anticancer research.

[4]  S. Kaveri,et al.  Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. , 2006, Cancer letters.

[5]  H. Franz,et al.  Isolation and properties of three lectins from mistletoe (Viscum album L.). , 1981, The Biochemical journal.

[6]  F. Stirpe,et al.  Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). , 1982, The Journal of biological chemistry.

[7]  P. Giacomini,et al.  Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Herrmann,et al.  A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. , 1995, Natural immunity.

[9]  A. Büssing,et al.  Expression of interleukin-4 in apoptotic cells: stimulation of the type-2 cytokine by different toxins in human peripheral blood mononuclear and tumor cells. , 2000, Cytometry.

[10]  A. Houghton,et al.  Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. , 1993, The Journal of clinical investigation.

[11]  B. Schneider,et al.  Results from a multicenter, comparative, epidemiological cohort study in Germany , 2005 .

[12]  M. Baccarani,et al.  Generation of Dendritic Cells from Positively Selected CD14 +  Monocytes for Anti-tumor Immunotherapy , 2004, Leukemia & lymphoma.

[13]  F. Sallusto,et al.  Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.

[14]  A. Enk,et al.  Induction of tolerance by IL-10-treated dendritic cells. , 1997, Journal of immunology.

[15]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[16]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[17]  S Ferrone,et al.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.

[18]  F. Brasseur,et al.  A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.

[19]  R. Steinman,et al.  Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. , 1999, Human immunology.

[20]  A. Anichini,et al.  T-cell response to unique and shared antigens and vaccination of cancer patients. , 2002, Cancer immunity.

[21]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[22]  T. Chao,et al.  Analysis of host versus tumor interaction in cancer patients: opposing role of transforming growth factor-beta1 and interleukin-6 in the development of in situ tumor immunity. , 2005, Immunobiology.

[23]  R. Wolfram,et al.  Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer , 2000, International journal of cancer.

[24]  A. Büssing,et al.  Toxic proteins from European mistletoe (Viscum album L.): increase of intracellular IL-4 but decrease of IFN-gamma in apoptotic cells. , 2000, Anticancer research.

[25]  R. Wolfram,et al.  Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. , 2006, European journal of medical research.

[26]  F. Jotereau,et al.  Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions , 1996, The Journal of experimental medicine.

[27]  P. Dalerba,et al.  Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction , 2002, Immunological reviews.

[28]  T. Khwaja,et al.  Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. , 1986, Oncology.

[29]  S. Kaveri,et al.  Molecular Mechanisms Underlying the Immunomodulatory Effects of Mistletoe (Viscum album L.) Extracts Iscador , 2006, Arzneimittelforschung.

[30]  J. Beuth,et al.  Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. , 2005, Anticancer research.

[31]  S. Lyu,et al.  Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. , 2001, Cancer biotherapy & radiopharmaceuticals.

[32]  L. Heinzerling,et al.  Immunologic Effector Mechanisms of a Standardized Mistletoe Extract on the Function of Human Monocytes and Lymphocytes in vitro, ex vivo, and in vivo , 2006, Journal of Clinical Immunology.

[33]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[34]  K. Urech,et al.  Viscotoxins, Mistletoe Lectins and their Isoforms in Mistletoe (Viscum album L.) Extracts Iscador , 2006, Arzneimittelforschung.

[35]  A. Büssing,et al.  Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. , 2002, Anticancer research.